Silexion Therapeutics (SLXN) Competitors $3.52 -0.04 (-1.12%) Closing price 10/17/2025 03:59 PM EasternExtended Trading$3.57 +0.05 (+1.42%) As of 10/17/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SLXN vs. TPST, CALC, BCAB, ESLA, NBRV, NEUP, SNTI, PDSB, FGEN, and ZIVOShould you be buying Silexion Therapeutics stock or one of its competitors? The main competitors of Silexion Therapeutics include Tempest Therapeutics (TPST), CalciMedica (CALC), BioAtla (BCAB), Estrella Immunopharma (ESLA), Nabriva Therapeutics (NBRV), Neuphoria Therapeutics (NEUP), Senti Biosciences (SNTI), PDS Biotechnology (PDSB), FibroGen (FGEN), and ZIVO Bioscience (ZIVO). These companies are all part of the "pharmaceutical products" industry. Silexion Therapeutics vs. Its Competitors Tempest Therapeutics CalciMedica BioAtla Estrella Immunopharma Nabriva Therapeutics Neuphoria Therapeutics Senti Biosciences PDS Biotechnology FibroGen ZIVO Bioscience Silexion Therapeutics (NASDAQ:SLXN) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment. Do insiders and institutionals hold more shares of SLXN or TPST? 11.0% of Silexion Therapeutics shares are held by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are held by institutional investors. 6.0% of Silexion Therapeutics shares are held by insiders. Comparatively, 4.7% of Tempest Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has stronger earnings and valuation, SLXN or TPST? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSilexion TherapeuticsN/AN/A-$16.44MN/AN/ATempest TherapeuticsN/AN/A-$41.84M-$14.59-0.69 Do analysts rate SLXN or TPST? Silexion Therapeutics currently has a consensus target price of $75.00, suggesting a potential upside of 2,030.68%. Tempest Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 195.86%. Given Silexion Therapeutics' higher probable upside, research analysts plainly believe Silexion Therapeutics is more favorable than Tempest Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silexion Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Tempest Therapeutics 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 Does the media favor SLXN or TPST? In the previous week, Silexion Therapeutics had 1 more articles in the media than Tempest Therapeutics. MarketBeat recorded 1 mentions for Silexion Therapeutics and 0 mentions for Tempest Therapeutics. Silexion Therapeutics' average media sentiment score of 1.00 beat Tempest Therapeutics' score of 0.00 indicating that Silexion Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Silexion Therapeutics Positive Tempest Therapeutics Neutral Which has more volatility and risk, SLXN or TPST? Silexion Therapeutics has a beta of -0.07, meaning that its share price is 107% less volatile than the S&P 500. Comparatively, Tempest Therapeutics has a beta of -2.08, meaning that its share price is 308% less volatile than the S&P 500. Is SLXN or TPST more profitable? Silexion Therapeutics' return on equity of 0.00% beat Tempest Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Silexion TherapeuticsN/A N/A -355.74% Tempest Therapeutics N/A -334.76%-130.63% SummarySilexion Therapeutics beats Tempest Therapeutics on 7 of the 11 factors compared between the two stocks. Get Silexion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLXN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SLXN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLXN vs. The Competition Export to ExcelMetricSilexion TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.13M$3.40B$6.10B$10.50BDividend YieldN/A2.29%5.73%4.81%P/E RatioN/A22.4484.5227.09Price / SalesN/A427.40585.94210.58Price / CashN/A46.5937.1661.22Price / Book-0.0910.4112.246.52Net Income-$16.44M-$52.47M$3.32B$276.75M7 Day Performance-9.28%2.32%1.25%2.00%1 Month Performance-2.49%11.14%6.28%2.26%1 Year Performance-92.93%11.15%59.92%35.58% Silexion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLXNSilexion Therapeutics3.2331 of 5 stars$3.52-1.1%$75.00+2,030.7%-92.5%$11.13MN/A0.00N/APositive NewsShort Interest ↓TPSTTempest Therapeutics1.4316 of 5 stars$10.82-0.2%$30.00+177.4%-32.2%$48.02MN/A-0.7420CALCCalciMedica3.2232 of 5 stars$3.40+4.6%$16.00+370.6%-18.9%$47.51MN/A-2.1230BCABBioAtla0.3331 of 5 stars$0.80-3.0%N/A-55.2%$46.62M$11M-0.7260News CoverageAnalyst ForecastESLAEstrella Immunopharma2.8588 of 5 stars$1.27-9.0%$16.00+1,155.9%+108.3%$46.52MN/A-4.83N/APositive NewsShort Interest ↓Gap DownHigh Trading VolumeNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070NEUPNeuphoria Therapeutics2.1402 of 5 stars$19.23-3.9%$28.00+45.6%N/A$45.38M$15.65M0.00N/ASNTISenti Biosciences3.3628 of 5 stars$1.73+3.6%$8.50+391.3%+0.0%$45.26M$2.56M-0.194Trending NewsAnalyst ForecastAnalyst RevisionPDSBPDS Biotechnology1.2288 of 5 stars$0.97+0.8%$10.00+930.9%-70.1%$45.19MN/A-1.0420FGENFibroGen3.9325 of 5 stars$11.11-1.8%$43.00+287.2%+5.1%$44.88M$29.62M-29.24570ZIVOZIVO Bioscience0.5587 of 5 stars$11.75-2.3%N/A-36.5%$44.85M$15.85K-2.4110News CoverageGap Down Related Companies and Tools Related Companies Tempest Therapeutics Alternatives CalciMedica Alternatives BioAtla Alternatives Estrella Immunopharma Alternatives Nabriva Therapeutics Alternatives Neuphoria Therapeutics Alternatives Senti Biosciences Alternatives PDS Biotechnology Alternatives FibroGen Alternatives ZIVO Bioscience Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLXN) was last updated on 10/18/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silexion Therapeutics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Silexion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
